ExScientia Ltd

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The firm has designed three drugs that are in phase 1 human clinical trials. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ExScientia reports robust Q4 earnings, poised for precision medicine growth

ExScientia's Q4 2022 earnings call highlighted strong financial performance, key collaborations, and advancements in pipeline programs. The company's focus on AI-driven precision medicine and solid cash position bode well for future growth. Challenges in program management and cost control exist, but opportunities for innovation and partnerships are abundant.

ExScientia reports 15% revenue growth, poised for precision medicine leadership

ExScientia Ltd delivered strong financial performance with a 15% increase in quarterly revenue and a robust cash position, driven by successful product launches and cost-saving initiatives.
The company's focus on personalized medicine, innovative product development, and strategic financial management positions it well for future growth and market leadership.
While facing challenges in molecule differentiation and cost efficiency, ExScientia has opportunities to leverage biomarkers, advance clinical programs, and expand market presence.

ExScientia advances clinical trials and precision medicine with strong financials

ExScientia's Q2 2023 earnings call showcased progress in clinical trials, precision medicine, and AI integration, supported by a strong financial position.
The company's focus on innovation, cost efficiency, and strategic partnerships positions them well for future growth and advancements in drug discovery.
Challenges lie in managing milestone payments, operational complexities, and staying competitive through biologics investments and partnerships.
Opportunities abound in expanding collaborations, attracting industry interest, and unveiling advancements in biologics for pipeline growth from 2024 onwards.

ExScientia excels in Q3, poised for growth in precision medicine

ExScientia's Q3 performance reflects progress in oncology programs, financial strength, and a focus on precision drug design and partnerships.
The company's strengths lie in its robust cash position, innovative approach to drug design, and operational efficiency influenced by past projects.
Challenges include market adaptability, program prioritization, and maintaining competitiveness, while opportunities exist in advancing the pipeline and leveraging partnerships for growth.

ExScientia reports robust Q4 earnings, eyes growth through innovation

ExScientia's Q4 2023 earnings call showcases strong financial and operational performance.
The company's focus on innovation, partnerships, and efficiency drives growth.
Challenges include competition, innovation sustainability, and quality maintenance.
Opportunities lie in business development, automation, and efficient drug creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom.

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Ben Taylor, CFO & Chief Strategy Officer and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:20 p.m. P.T. A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Media” section at www.investors.exscientia.ai. An archived replay of the webcast will be

Exscientia to Present at the BofA Securities 2022 Healthcare Conference

Exscientia's AI platform is used to identify promising molecules that can proceed to the next step of drug development by large pharmaceuticals like Sanofi.

Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline

OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today shared details of its participation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13 2022 at the Ernest N. Morial Convention Center in New Orleans, La. Exscientia scientists will present new research in three poster presentations. “We are looking forward to meeting with some of the world's leading cancer clinicians and researchers at this year's AACR mee

Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia's portfolio of investigational medicines. Exscientia's drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, D

Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer

Exscientia plc (EXAI) CEO Andrew Hopkins on Q4 2021 Results - Earnings Call Transcript

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations as well as financial results for the fourth quarter and full year 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, March 24 at 12:30 p.m. GMT / 8:30 a.m. ET to provide an overview of the company's end-to-end technology platform and progress towards automating drug discovery and development. Recent Highlights Progr

Exscientia Business Update for Fourth Quarter and Full Year 2021

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2021, on Wednesday, March 23, 2022 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. ET on Thursday, March 24, 2022, to provide an overview of the company's unique end-to-end technology platform and Exscientia's work to fully automate drug discovery and development. A

Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a program designed to source cellular functional assays from the global academic community to develop novel screens and identify targets and therapeutic candidates for unmet medical needs. The Xcellomics program was created by the two Oxford-based institutions to expedite early-stage drug discovery research – primarily con

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced the acceptance of three abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA. “The abstracts highlighted at AACR demonstrate the potential of our functional precision oncology tools to improve clinical and patient outcomes by guiding treatment and patient selection u

Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022

Frontier IP Group PLC (AIM:FIPP), an investor in early-stage companies, said it sold further shares in Exscientia PLC, an artificial intelligence (AI)-driven drug developer, for a net $4.3mln (£3.2mln). The specialist in commercialising intellectual property sold 207,299 American Depositary Shares (ADS) in Exscientia between February 1 and February 11.

Frontier IP sells further shares in Exscientia for £3.2mln

Here is how Exscientia PLC Sponsored ADR (EXAI) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?

OXFORD, England--(BUSINESS WIRE)--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence (AI), machine learning, and the design of protein structures in the discovery and development of novel drug candidates. Professor Deane joins Exscientia's technology leadership team, reporting to Chief Technology Officer, Garry Pairaudeau. Professor Deane

Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI

Frontier IP said it will post strong first half numbers following the recent IPO on Nasdaq of portfolio company Exscientia. “While it is clear there are many challenges facing markets and industry, we anticipate reporting a set of results for H1 2022 ahead of management expectations and continuing to build on progress in the balance of the financial year,” the investment company said in a statement.

Frontier IP to beat expectations after Exscientia IPO

Sanofi

Shares of Exscientia PLC ( EXAI , Financial) got a nice boost last week when the U.K.-based biotech announced it signed a research collaboration and license agreement with large drugmaker Sanofi SA ( SNY , Financial) that could be worth $5.2 billion.

Shares of Sanofi, Exscientia Rise on News of Collaboration

Shares of Exscientia EXAI, -2.05% jumped 14.3% in premarket trading on Friday after it announced a deal with Sanofi SNY, -0.24% to develop up to 15 new oncology and immunology drug candidates using Exscientia's artificial intelligence platform. Sanofi's stock was up 0.8%.

Sanofi, Exscientia sign development deal worth up to $5.2 billion

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO, Ben Taylor, CFO & Chief Strategy Officer, and Garry Pairaudeau, Chief Technology Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday, December 2, 2021 at 10:30 a.m. ET (3:30 p.m. GMT). A live webcast of the fireside chat will be available on the Company's website, under the “Investors & Me

Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

Exscientia plc (EXAI) CEO Andrew Hopkins on Q3 2021 Results - Earnings Call Transcript

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI): Recent advancements in the Company's pipeline, collaborations and operations as well as financial results for the third quarter ended September 30, 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail on the business models underlying the Company's pipeline of more than 25 programmes. Highlights Leveraging deep learning on patient tiss

Exscientia Business Update for Third Quarter 2021

OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, will report financial results for the third quarter ended September 30, 2021, on Wednesday, November 17, 2021 after U.S. market close. Following the announcement, the Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. ET on Thursday, November 18, 2021, to provide

Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021

VIENNA & OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), the Medical University of Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, today announced publication in Cancer Discovery, a journal of the American Association of Cancer Research, of final results from the EXALT-1 trial. The study, titled “Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Haematological Cancers and Identifies Exceptional Responders,

Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment Outcomes

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exercise of the underwriters' prev

Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters' Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement

News for ExScientia Ltd Stock (EXAI)